Ben Woolven

Ben Woolven

Business Strategy and Operations Partner

Ben is the Business Strategy and Operations Partner of Syncona Investment Management Ltd.

Ben joined Syncona from GlaxoSmithKline where he has over a decade of strategy development, business operations and project management experience. Latterly Ben worked with GlaxoSmithKline’s Chief Medical Officer, where he led reconfiguration of global and regional medical functions in anticipation of their evolving pharma portfolio. Prior to this, Ben held various strategy and operations roles building scientific teams, developing justifications for new scientific investments, leading project management offices and providing R&D consultancy support, including a secondment to L.E.K Consulting. Prior to joining GlaxoSmithKline Ben played a key role in the success of Domantis, an antibody fragment start-up, sold to GlaxoSmithKline for £230 million. Ben holds a PhD in Immunology.

Martin Murphy

Martin Murphy

Chief Executive Officer
Chris Hollowood

Chris Hollowood

Chief Investment Officer
Markus John

Markus John

Chief Medical Officer and Head of R&D
Edward Hodgkin

Edward Hodgkin

Senior Partner
Elisa Petris

Elisa Petris

Lead Partner
Magdalena Jonikas

Magdalena Jonikas

Lead Partner
Alex Hamilton

Alex Hamilton

Investment Partner
Michael Kyriakides

Michael Kyriakides

Investment Partner
Gonzalo Garcia

Gonzalo Garcia

Investment Partner
Alice Renard

Alice Renard

Investment Partner
Raghd Rostom

Raghd Rostom

Associate Partner
Nathaniel Dahan

Nathaniel Dahan

Associate Partner
Lisa Bright

Lisa Bright

Commercial Advisor
Gwenaelle Pemberton

Gwenaelle Pemberton

Regulatory Advisor